Trial Profile
A Phase I/II Safety and Dose Evaluation Study of OXB-102 (AXO-Lenti-PD) in Patients With Bilateral Idiopathic Parkinson's Disease (SUNRISE-PD)
Status:
Discontinued
Phase of Trial:
Phase I/II
Latest Information Update: 16 May 2022
Price :
$35
*
At a glance
- Drugs AXO Lenti PD (Primary)
- Indications Parkinson's disease
- Focus Adverse reactions
- Acronyms SUNRISE-PD
- Sponsors Oxford BioMedica; Sio Gene Therapies [CEASED]
- 27 Apr 2022 Status changed from active, no longer recruiting to discontinued.
- 31 Jan 2022 According to an Oxford BioMedica media release, to date, six patients have been dosed.
- 04 Oct 2021 According to a Sio Gene Therapies media release, data from this study will be presented at the European Society of Gene & Cell Therapy (ESGCT) Virtual Congress 2021